Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EPS (Weighted Average and Diluted) (2023 - 2025)

Vistagen Therapeutics' EPS (Weighted Average and Diluted) history spans 9 years, with the latest figure at -$0.45 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 2.17% year-over-year to -$0.45; the TTM value through Dec 2025 reached -$1.91, down 29.05%, while the annual FY2025 figure was -$1.67, 9.87% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.45 at Vistagen Therapeutics, up from -$0.55 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.28 in Q4 2023 and bottomed at -$0.94 in Q2 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.45 (2025), against an average of -$0.42.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 62.77% in 2024 against a maximum downside of 264.29% in 2024.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.28 in 2023, then tumbled by 264.29% to -$0.46 in 2024, then increased by 2.17% to -$0.45 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's EPS (Weighted Average and Diluted) are -$0.45 (Q4 2025), -$0.55 (Q3 2025), and -$0.47 (Q2 2025).